Diagnostic Value of Immunological Leukemia Phenotyping

Drexler, Hans G.; Menon, Mira; Gignac, Suzanne M.; Misra, Bishnupria; Minowada, Jun

doi:10.1159/000206008

Cited by 8 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AML thus differs from acute lymphoblastic leukemia (ALL) in which the primacy of morphology is complemented by blast cell immunophenotyping; four main subtypes, of similar morphological appearances, have thus been identified (Chessels et al, 1977). More recently monoclonal antibodies (mAbs) defining granulocytic, monocytic, erythroid, and megakaryocytic lineages have been increasingly used to support the diagnosis of AML (Drexler et al, 1986a;Neame et al, 1986;Foon et al, 1986;Messner and Griffin, 1986;Wain and Borowitz, 1987).…”

Section: Introductionmentioning

confidence: 99%

Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome

Tucker

Dorey

Gregory

et al. 1990

Hematological Oncology

View full text Add to dashboard Cite

The immunophenotype of peripheral blood blast cells was tested in 92 patients with acute myeloid leukemia (AML), who were diagnosed and treated at single centre, St Bartholomew's Hospital, from 1978-1987 with a standard adriamycin, cytosine arabinoside and 6-thioguanine regimen. Immunological analysis involved standard fluorescence flow cytometry and utilized 31 monoclonal antibodies to known myeloid antigens (of CD groups 11b, 11c, 13, 14, 15, 16, w17, 31, w32, 33, 34, 35 and 36), a number of relatively less well studied antibodies with potential specificity for AML, and a series of control antibodies to T and B lymphocytes, platelets, erythrocytes and of widespread distribution (CD45, leucocyte common; HLA-DR). The results highlighted a number of antibodies with wide myeloid reactivity, in addition to CD13 and 33 (present in 66 per cent and 76 per cent of cases, respectively), which may be of immunodiagnostic use. A number of correlations between AML cell immunophenotype and FAB morphology subtype were found; in particular five antibodies (CD11c, 10.1, Tu3, CD15 and CD16), of both predominant granulocytic and monocytic reactivity, reacted with cells of AML-M5 subtype (p less than 0.05). There was no significant correlation between immunophenotype and clinical and pathological features at presentation. Correlation with clinical outcome was not a prominent feature, in contrast to some reports based on multicentre data. However, of particular note was the strong association between early death (at less than 2 months) and the coexpression of Leucocyte Function Associated (LFA) antigens, CD11b and 11c, on patient's blast cells (p = 0.003). The relationship was independent of clinical features and persisted even if AML-M5 cases were excluded. The significance of this latter finding is unclear, but may be related to the known role of CD11b and 11c LFA antigens in the cellular response to infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome

Tucker

Dorey

Gregory

et al. 1990

Hematological Oncology

View full text Add to dashboard Cite

show abstract

Correlations between acute lymphoid leukemia (ALL) immunophenotype and clinical and laboratory data at presentation. A study of 350 patients

Garand¹,

Vannier

Béné³

et al. 1989

Cancer

View full text Add to dashboard Cite

The phenotypes of malignant cells from 350 untreated patients with acute lymphoblastic leukemia (ALL) were determined at diagnosis with the use of a panel of monoclonal antibodies to leukocyte antigens. According to the phenotypes seen, the cases were divided into five groups, pre-B ALL, B-ALL, T-ALL, MO-ALL, and undifferentiated ALL. Each group was subdivided, resulting in 11 defined immunologic subtypes. Correlations between clinical and laboratory features were investigated at presentation. ALL of early-B phenotype associated with elevated cell counts occurred more often in female and infant patients than in male patients. Involvement of the central nervous system was frequent in B-ALL, which occurred mostly in male patients. A male prevalence was also seen in ALL of T-lineage in which significant differences regarding clinical characteristics and leukocyte counts appeared among the four subtypes. The clinical relevance of phenotypic subcategorization is supported by our observations.

show abstract

Incidence and Clinical Relevance of Myeloid Antigen-Positive Acute Lymphoblastic Leukemia

Drexler

Ludwig

1993

Recent Advances in Cell Biology of Acute Leukemia

View full text Add to dashboard Cite

Diagnostic Value of Immunological Leukemia Phenotyping

Cited by 8 publications

References 7 publications

Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome

Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome

Correlations between acute lymphoid leukemia (ALL) immunophenotype and clinical and laboratory data at presentation. A study of 350 patients

Incidence and Clinical Relevance of Myeloid Antigen-Positive Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About